ALKBH5 and non-small cell lung carcinoma: Moreover, the ALKBH5‐FBXL5 axis reduced ROS levels, inhibited the activation of the PI3K‐AKT and NF‐κB pathway, and ultimately impaired NSCLC malignancy.